<DOC>
	<DOCNO>NCT01828489</DOCNO>
	<brief_summary>This study evaluate effect different induction course child adolescent newly diagnose acute myeloid leukemia . In first course patient randomise receive either standard anthracycline therapy mitoxantrone experimental DaunoXome . In second course patient randomised standard treatment ADxE ( cytarabine , DaunoXome , etoposide ) experimental therapy FLADx ( fludarabine , cytarabine , DaunoXome ) .</brief_summary>
	<brief_title>Research Study Treatment Children Adolescents With Acute Myeloid Leukaemia 0-18 Years</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>1 . AML define WHO diagnostic criterion 2 . Age &lt; 19 year time diagnosis 3 . Written inform consent 1 . Previous chemotherapy radiotherapy . This include patient secondary AML previous cancer therapy 2 . AML secondary previous bone marrow failure syndrome . 3 . Down syndrome ( DS ) 4 . Acute promyelocytic leukaemia ( APL ) 5 . Myelodysplastic syndrome ( MDS ) 6 . Juvenile Myelomonocytic Leukaemia ( JMML ) 7 . Known intolerance chemotherapeutic drug protocol . 8 . Fanconi anaemia 9 . Major organ failure preclude administration plan chemotherapy . 10 . Positive pregnancy test 11 . Lactating female female childbearing potential use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>